STATOBEX-G Drug Patent Profile
✉ Email this page to a colleague
When do Statobex-g patents expire, and when can generic versions of Statobex-g launch?
Statobex-g is a drug marketed by Teva and is included in one NDA.
The generic ingredient in STATOBEX-G is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Statobex-g
A generic version of STATOBEX-G was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
Summary for STATOBEX-G
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Patent Applications: | 1,999 |
Formulation / Manufacturing: | see details |
DailyMed Link: | STATOBEX-G at DailyMed |
US Patents and Regulatory Information for STATOBEX-G
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | STATOBEX-G | phendimetrazine tartrate | TABLET;ORAL | 085095-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |